The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%. The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.
The biologics manufacturing segment is expected to grow at the highest rate during the forecast period. On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services.The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period.
Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.
The big pharma end user segment is expected to account for the largest market share in 2019. The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.
The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market. Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.
A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (21%), Tier 2 (26%), and Tier 3 (53%) • By Designation: C-level (32%), Director-level (26%), and Others (42%) • By Region: North America (35%), Europe (30%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (10%)
The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific (US), Catalent (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), and Siegfried Holding AG (Switzerland).
Research Coverage: This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns.It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments.
The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.
Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers: • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global pharmaceutical contract development and manufacturing market • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global pharmaceutical contract development and manufacturing market • Market Development: Comprehensive information on the lucrative emerging regions • Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global pharmaceutical contract development and manufacturing market • Competitive Assessment: In-depth assessment of market ranking, growth strategies, revenue analysis, and services of leading players in the global pharmaceutical contract development and manufacturing market
Our reports have been used by over 10K customers, including:
The particle counters market is projected to grow at a CAGR of 9.9% during the forecast period, to reach USD 554million by 2025 from USD 346million in 2020. The growth in thismarket is driven by the robust growth in applied markets, the favorable regulatory scenario, and growing focus on the quality of food products. In addition, emerging...
The Global Pharmaceutical CDMO Market was valued USD 160.12 billion in 2020, and it is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19...
India - Healthcare, Regulatory and Reimbursement Landscape Summary The analyst has released its latest report: “India - Healthcare, Regulatory and Reimbursement Landscape”.The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in India. It...
275 pages •
By Asia Market Information & Development Company
• Jan 2021
China’s demand for Pharmaceuticals has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
The global pharmaceutical membrane filtration market is estimated to grow from USD 5.8 billion in 2020 to reach USD 10.2 billion by 2025, at a CAGR of 12.0% during the forecast period. The rising adoption of single-use technologies, rapid growth in the pharmaceutical and biopharmaceutical industries, and the growing demand for nanofiltration...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
The Peptide Therapeutics Market is valued at approximately USD 28,510.60 million in 2020 and is expected to witness a revenue of USD 51,360.30 million in 2026, with a CAGR of 9.66% over the forecast period (2021-2026). Novel peptides are being developed and repurposed as therapeutics for the treatment of COVID-19. Globally, researchers...
The water soluble polymer market is expected to register a CAGR of over 4% during the forecast period. The factors driving the growth of the market studied are the growing shale gas industry in North America and the water treatment industry in the Asia-Pacific region. - On the flip side, other than the impact of COVID-19 pandemic on...
The mass spectrometry market size is expected to grow from an estimated USD 4.1 billion in 2020 to USD 5.6 billion by 2025, at a CAGR of 6.5%. Increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and growing...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
Gross Domestic Expenditure On R&D
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.